<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772653</url>
  </required_header>
  <id_info>
    <org_study_id>CSPT-CG-PPT1</org_study_id>
    <nct_id>NCT02772653</nct_id>
  </id_info>
  <brief_title>Evaluation of Resuscitation Markers in Trauma Patients</brief_title>
  <official_title>Evaluation of Resuscitation Markers in Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrea Campos-Serra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe trauma patients have an elevated risk of multiple organ failure and death. In order to
      increase survival possibilities the initial treatment must be focused into resuscitation from
      shock. Traditionally the most common resuscitation markers used are vital signs and urine
      output. Unfortunately, many patients might present normal vital signs, but still undergo a
      compensated shock with persistent acidosis, hence being able to develop multiple organ
      failure and death. Consequently, it is important to define better resuscitation markers for
      these patients.

      This investigation project consists in an observational prospective study, performed by a
      multidisciplinary team, in which different resuscitation markers are evaluated in severe
      trauma patients. There will be a specific timing (1st, 8th and 24th hours from arrival)
      evaluation of different markers: hemodynamic (vital signs, urine output, etc); analytical
      (lactate, base excess, natriuretic atrial peptide); tissue perfusion markers (NIRS);
      microcirculation markers (videomicroscopy) and coagulopathy markers (thromboelastometry).
      There will be a registry of total volume administration; blood cell transfusions and
      vasoactive drug requirements. Each marker will be evaluated in relation to mortality;
      multiple organ failure; massive transfusion protocol activation; blood cell transfusion
      requirement; surgical control of bleeding requirement and emergent arteriographic
      embolization. The objective of this study is to demonstrate which of these markers is better
      to predict hemodynamic evolution of severe trauma patients and might become a guide for
      resuscitation in the future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Through study completion, an average of 1-2 years</time_frame>
    <description>Death of the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple organ dysfunction (Multiple Organ Dysfunction Score)</measure>
    <time_frame>Through study completion, an average of 1-2 years</time_frame>
    <description>Marshall's score (MODS Score) consist on the analysis of 6 systems through different descriptors, those descriptors include: a) the respiratory system (pO2/FIO2 ratio); b) the renal system (serum creatinine concentration); c) the hepatic system (serum bilirrubine concentration); d) the hematologic system (platelet count); and e) the central nervous system (Glasgow Coma Scale); and f) the cardiovascular system (pressure adjusted heart rate). The cardiovascular system descriptor is calculated as the product of the heart rate and the ratio of central venous pressure to mean arterial pressure. All these descriptors will be measured during the first 24h from hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cell transfusion</measure>
    <time_frame>Through study completion, an average of 1-2 years</time_frame>
    <description>Need for blood cell transfusion for patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of the Massive blood transfusion protocol</measure>
    <time_frame>At hospital admission</time_frame>
    <description>Need for massive transfusion protocol activation on patients with suspicion of active bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical intervention for bleeding control</measure>
    <time_frame>Through study completion, an average of 1-2 years</time_frame>
    <description>Need for surgical control on patients with active bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arteriographic embolization for bleeding control</measure>
    <time_frame>Through study completion, an average of 1-2 years</time_frame>
    <description>Need for arteriographic embolization on patients with active bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Through study completion, an average of 1-2 years</time_frame>
    <description>Number of days that the patient remains in hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensive care unit stay</measure>
    <time_frame>Through study completion, an average of 1-2 years</time_frame>
    <description>Number of days that the patient remains in the intensive care unit</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Trauma</condition>
  <condition>Hypovolemic Shock</condition>
  <arm_group>
    <arm_group_label>Severe trauma patients</arm_group_label>
    <description>No interventions are done. It's a prospective and descriptive observational study where different markers are analyzed:
Blood Lactate levels
Blood Base Excess levels
Blood B-type Natriuretic Peptide levels
Blood Thromboelastometry (ROTEM) alterations
Near-infrared spectroscopy alterations
Sublingual videomicroscopy alterations
All these markers are analyzed at the 1rst, 8th and 24th hour from hospital admission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Lactate</intervention_name>
    <description>Analyzed at the 1rst, 8th and 24th hour from hospital admission</description>
    <arm_group_label>Severe trauma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Base Excess</intervention_name>
    <description>Analyzed at the 1rst, 8th and 24th hour from hospital admission</description>
    <arm_group_label>Severe trauma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood B-type Natriuretic Peptide</intervention_name>
    <description>Analyzed at the 1rst, 8th and 24th hour from hospital admission</description>
    <arm_group_label>Severe trauma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Thromboelastometry (ROTEM)</intervention_name>
    <description>Analyzed at the 1rst, 8th and 24th hour from hospital admission</description>
    <arm_group_label>Severe trauma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Near-infrared spectroscopy</intervention_name>
    <description>Analyzed at the 1rst, 8th and 24th hour from hospital admission</description>
    <arm_group_label>Severe trauma patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sublingual videomicroscopy</intervention_name>
    <description>Analyzed at the 1rst, 8th and 24th hour from hospital admission</description>
    <arm_group_label>Severe trauma patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for Natriuretic Peptide analysis. Retained just for one month, until samples
      are analyzed at an external laboratory.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Severe trauma patients admitted at Corporacio Sanitaria Parc Tauli
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-hospital Priority 0 protocol activation:

          -  Glasgow coma scale &lt; 14

          -  Systolic blood pressure &lt; 90 mmHg

          -  Respiratory rate &lt; 10 or &gt; 29 breaths per minute

          -  Absent peripheral pulses

          -  Pre-hospital Priority 1 protocol activation:

          -  All penetratin injuries to head, neck, torso and extremities proximal to elbow and
             knee

          -  Flail chest

          -  Two or more proximal long-bone fractures

          -  Crushed, degloved or mangled extremity

          -  Amputation proximal to wrist and ankle

          -  Pelvic fracture

          -  Open or depressed skull fracture

          -  Paralysis

        Exclusion Criteria:

          -  Hospitalization &lt; 24 hours ( transport of the patient to an other trauma center)

          -  Patients transported from an other hospital (first hours of medical support done
             elsewhere)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Campos-Serra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporacion Sanitaria Parc Tauli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvador Navarro-Soto, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Corporacion Sanitaria Parc Tauli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Montmany-Vioque, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Corporacion Sanitaria Parc Tauli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Campos-Serra, MD</last_name>
    <phone>0034617141687</phone>
    <email>acampos@tauli.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salvador Navarro-Soto, MD, PhD</last_name>
    <email>snavarro@tauli.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Corporacion Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Campos Serra, MD</last_name>
      <phone>0034617141687</phone>
      <email>acampos@tauli.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Andrea Campos-Serra</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Microcirculation</keyword>
  <keyword>Videomicroscopy</keyword>
  <keyword>Spectroscopy, Near-Infrared</keyword>
  <keyword>B-Type Natriuretic Peptide</keyword>
  <keyword>Thromboelastometry</keyword>
  <keyword>Trauma</keyword>
  <keyword>Resuscitation</keyword>
  <keyword>Hypovolemic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

